A5057918523- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Statistical Methods in Clinical Trials
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Biosimilars and Bioanalytical Methods
- PARP inhibition in cancer therapy
- BRCA gene mutations in cancer
- Pharmacogenetics and Drug Metabolism
- Advanced Breast Cancer Therapies
- Lipoproteins and Cardiovascular Health
- Multiple and Secondary Primary Cancers
- Advanced Causal Inference Techniques
- Radiomics and Machine Learning in Medical Imaging
- Computational Drug Discovery Methods
- Cancer survivorship and care
University of Pittsburgh
2016-2025
NRG Oncology
2016-2025
Twitter (United States)
2025
NSABP Foundation
2013-2023
McKesson (United States)
2017
Texas Oncology
2017
Baylor University Medical Center
2017
University of Florida
2009-2016
NewYork–Presbyterian Hospital
2016
University of Pennsylvania
2009-2016
We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women surgically removed HER2-positive breast cancer.
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and colon cancer.Patients who had undergone a potentially curative resection were randomly assigned either FU 500 mg/m2 intravenous (IV) 6 weeks plus IV during each 8-week cycle three cycles (FULV), or same FULV regimen 85 administered 1, 3, 5 (FLOX).A total 2,407 patients (96.6%) 2,492...
Purpose Although chemoradiotherapy plus resection is considered standard treatment for operable rectal carcinoma, the optimal time to administer this therapy not clear. The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant in of locally advanced carcinoma. Patients Methods with clinical T3 or T4 node-positive cancer were randomly assigned preoperative postoperative chemoradiotherapy. Chemotherapy consisted fluorouracil leucovorin...
Trastuzumab is effective in treating human epidermal growth factor receptor 2 (HER2) -positive breast cancer, but it increases frequency of cardiac dysfunction (CD) when used with or after anthracyclines.National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin cyclophosphamide (AC) followed by paclitaxel AC plus 52 weeks trastuzumab beginning concurrently patients node-positive, HER2-positive cancer. Initiation required normal post-AC left ventricular ejection...
The primary aim of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 was to determine whether four cycles adjuvant paclitaxel (PTX) after doxorubicin/cyclophosphamide (AC) will prolong disease-free survival (DFS) overall (OS) compared with AC alone in patients resected operable breast cancer histologically positive axillary nodes.Between August 1995 May 1998, 3,060 were randomly assigned (AC, 1,529; followed by PTX [AC --> PTX], 1,531). Patients > or = 50 years those younger...
The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that the addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) in patients with stage II or III colon cancer. This analysis is first publication overall (OS) for NSABP study. We updated DFS examined both end points clinically relevant patient subsets.
Limited data are available on the time course of treatment failures (recurrence and/or death), nature and duration adjuvant benefit, long-term recurrence rates in patients with resected stage II III colon cancer.
The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the safety efficacy of adding bevacizumab modified FOLFOX6 (mFOLFOX6; ie, infusional/bolus fluorouracil, leucovorin, oxaliplatin) for adjuvant treatment patients with stages II III colon cancer.Patients received mFOLFOX6 every 2 weeks 26 alone or as + (5 mg/kg 52 [ie, experimental group]). primary end point disease-free survival (DFS).Among 2,672 analyzed patients, demographic factors were well...
Trastuzumab (Herceptin) provides clinical benefits for patients diagnosed with advanced breast cancers that have overexpressed the HER2 protein or amplified gene. The National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-31 is designed to test advantage of adding Herceptin adjuvant chemotherapeutic regimen doxorubicin cyclophosphamide followed by paclitaxel (Taxol) in treatment stage II cancer overexpression gene amplification. Eligibility based on assay results submitted...
Purpose Cardiac dysfunction (CD) is a recognized risk associated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer, especially when treatment regimen includes anthracyclines. Given demonstrated efficacy trastuzumab, ongoing assessment cardiac safety and identification factors CD are important optimal patient care. Patients Methods In National Surgical Adjuvant Breast Bowel Project B-31, phase III trial, 1,830...
Approximately 15% of colorectal cancers develop because defective function the DNA mismatch repair (MMR) system. We determined association MMR status with colon cancer recurrence and examined impact 5-fluorouracil (FU)-based adjuvant therapy on variables. included stage II III carcinoma patients (n = 2141) who were treated in randomized trials 5-FU-based therapy. Tumors analyzed for microsatellite instability by polymerase chain reaction and/or protein expression immunohistochemistry to...
The identification of high-risk stage II colon cancers is key to the selection patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor hold promise, but they are difficult use in clinical practice.
The optimal chemotherapy regimen administered concurrently with preoperative radiation therapy (RT) for patients rectal cancer is unknown. National Surgical Adjuvant Breast and Bowel Project trial R-04 compared four regimens concomitantly RT.Patients clinical stage II or III who were undergoing RT (45 Gy in 25 fractions over 5 weeks plus a boost of 5.4 to 10.8 three six daily fractions) randomly assigned one the following regimens: continuous intravenous infusional fluorouracil (CVI FU; 225...
Background: Although several studies have established a link between obesity and colon cancer risk, little is known about the effect of on outcomes after diagnosis. We investigated association body mass index (BMI) with in patients from cooperative group clinical trials. Methods: The study cohort consisted 4288 Dukes B C who were accrued July 1989 to February 1994 National Surgical Adjuvant Breast Bowel Project randomized Risk recurrence, second primary cancer, mortality (overall by likely...
The primary aim of this study was to compare the relative efficacy oral uracil and tegafur (UFT) plus leucovorin (LV) with weekly intravenous fluorouracil (FU) LV in prolonging disease-free survival (DFS) overall (OS) after surgery for colon carcinoma.Between February 1997 March 1999, 1,608 patients stage II III carcinoma were randomly assigned receive either UFT+LV or FU+LV.Of total patients, 47% had cancer, 53% cancer. Median follow-up time 62.3 months. estimated hazard ratio (HR) OS who...
National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabine could be substituted for continuous infusion 5-FU in curative setting of stage II/III rectal cancer during neoadjuvant radiation therapy addition oxaliplatin further enhance activity fluoropyrimidine-sensitized radiation. Patients with clinical II or III undergoing preoperative were randomly assigned one four chemotherapy regimens a 2x2 design: CVI without...
The purpose of this study was to examine the prognostic and oxaliplatin predictive value mismatch repair (MMR) status common hot spot mutations, which we previously identified in stage II III colon cancer.Mutations BRAF, KRAS, NRAS, MET, PIK3CA were profiled 2,299 tumors from National Surgical Adjuvant Breast Bowel Project (NSABP) clinical trials C-07 (n = 1,836) C-08 463) with Type Plex chemistry mass spectrometry. tested worth adding 5-fluorouracil plus leucovorin, bevacizumab FOLFOX. Cox...
These studies were conducted to determine the relationship between quantitative tumor gene expression and risk of cancer recurrence in patients with stage II or III colon treated surgery alone plus fluorouracil (FU) leucovorin (LV) develop multigene algorithms quantify as well likelihood differential treatment benefit FU/LV adjuvant chemotherapy for individual patients.We performed reverse transcription polymerase chain reaction (RT-qPCR) on RNA extracted from fixed, paraffin-embedded (FPE)...
Purpose Docetaxel and cyclophosphamide (TC) was superior to doxorubicin (AC) in a trial early breast cancer. However, activity of TC relative AC regimens with taxane (TaxAC) is unknown. Methods In series three adjuvant trials, women were randomly assigned for six cycles (TC6) or standard TaxAC regimen. US Oncology Research (USOR) 06-090 compared TC6 docetaxel, doxorubicin, (TAC6). National Surgical Adjuvant Breast Bowel Project (NSABP) B-46-I/USOR 07132 TC6, TAC6, plus bevacizumab. NSABP...
Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) are now standard. We examined the impact age on recurrence mortality after these newer options. Patients Methods analyzed 11,953 < 70 2,575 ≥ years seven trials comparing IV FU fluoropyrimidines (capecitabine, uracil, or tegafur) combinations oxaliplatin...
<h3>Importance</h3> Total neoadjuvant therapy (TNT) is often used to downstage locally advanced rectal cancer (LARC) and decrease locoregional relapse; however, more than one-third of patients develop recurrent metastatic disease. As such, novel combinations are needed. <h3>Objective</h3> To assess whether the addition pembrolizumab during after chemoradiotherapy can lead an improvement in (NAR) score compared with treatment FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) alone. <h3>Design,...